Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03268551 · ClinicalTrials.gov registry record

MEMO-Medical Marijuana and Opioids Study

A clinical trial of Chronic Pain and Opioid Use, sponsored by Albert Einstein College of Medicine.

Completed
Registry status
257
Enrollment target
2
Study locations

NCT03268551 is a study of Chronic Pain and Opioid Use that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 257 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (67% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03268551, a study of Chronic Pain and Opioid Use, has completed, sponsored by Albert Einstein College of Medicine.

COMPLETED
Registry status
257 participants
Enrollment target
2
Study locations

Study Summary

The study will examine how medical cannabis use affects opioid analgesic use over time, with particular attention to THC/CBD content, HIV outcomes, and severe adverse events.

Study Locations (2)

New York

  • Montefiore Health System - The Bronx
  • Vireo Health - White Plains

Trial Details

FieldValue
Enrollment Target 257 participants
Start Date 2018-09-04
Est. Completion 2023-07-14

Sponsor

Albert Einstein College of Medicine

175 total trials

What the Registry Record Tells You About NCT03268551

The ClinicalTrials.gov registry entry for NCT03268551 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 257 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (67% lower). The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Chronic Pain appearing as the primary indexed condition, and to 0 interventions.

NCT03268551 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03268551 about?

NCT03268551 is a clinical study titled "MEMO-Medical Marijuana and Opioids Study". The study will examine how medical cannabis use affects opioid analgesic use over time, with particular attention to THC/CBD content, HIV outcomes, and severe adverse events.

What is the current status of trial NCT03268551?

This trial is currently completed. The enrollment target is 257 participants. The study started on 2018-09-04. Estimated completion is 2023-07-14.

What conditions does trial NCT03268551 study?

This clinical trial studies the following conditions: Chronic Pain, Opioid Use, HIV/AIDS, Marijuana.

Who is sponsoring clinical trial NCT03268551?

This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03268551 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.